Printer Friendly

REGENEREX, INC. APPOINTS PRESIDENT, COO TO LEAD DEVELOPMENT PROGRAM FOR ARTIFICIAL LIVER

 MINNEAPOLIS, Nov. 2 /PRNewswire/ -- Regenerex, Inc. announced today it has taken a major step toward building its management team with the appointment of Dr. Daniel G. Miller as president and chief operating officer. Regenerex, a development-stage company, has been organized to commercialize a bio-artificial liver (BAL) technology which has been under development at Cellex Biosciences, Inc. (NASDAQ: CLXX) and the University of Minnesota for the past several years. The device utilizing this technology is expected to supplement or even temporarily replace liver function in patients suffering from acute liver failure.
 Dr. Miller's previous experience includes eight years as the head of the biotechnology effort at 3M Company and for the past five years as vice president of research and development at Dianon Systems, Inc., a publicly held firm providing laboratory services and information products to physicians in oncology and gynecology.
 Reacting to this appointment, Dr. Miller emphasized that, "the opportunity to pioneer the development of an unprecedented solution to a difficult medical problem as being a major factor in deciding to join this effort. It isn't often that a new medical technology has the potential to both save lives and reduce health-care costs, but that is the objective of the bio-artificial liver."
 Richard E. Sakowicz, president and chief operating officer of Cellex Biosciences, Inc. commented, "We transferred the BAL technology from Cellex Biosciences to Regenerex to create a focused team devoted to the development of the BAL device, seeing it through the FDA approval process and ultimately to commercialization. Given its excellent record of medical device development and commercialization, its talented employee base and proximity to the University of Minnesota, the Twin Cities are an especially productive environment for new biomedical device development."
 Cellex Biosciences, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health-care and biotechnology markets worldwide.
 Regenerex, Inc., located in Minneapolis, is committed to the development of a bio-artificial liver device designed to sustain liver function in patients suffering from acute liver failure.
 -0- 11/2/93
 /CONTACT: Yvonne L. Marschner-Bova, director, Investor Relations, Cellex Biosciences, Inc., 313-871-7350/
 (CLXX)


CO: Cellex Biosciences, Inc.; Regenerex, Inc. ST: Minnesota IN: MTC SU: PER

DC -- DE030 -- 9768 11/02/93 15:46 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 2, 1993
Words:373
Previous Article:UNITED AMERICAN HEALTHCARE ANNOUNCESRECORD FIRST-QUARTER EARNINGS, REVENUES
Next Article:CORE INDUSTRIES INC ANNOUNCES DIVIDEND
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters